TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Previous participation in Phase 1 Gilead clinical trial~* Diagnosis of idiopathic pulmonary fibrosis~* Females of childbearing potential and non-vasectomized males must agree to use highly effective methods of contraception~* Females must discontinue nursing~* Comply with study requirements~* Have adequate organ function~Key Exclusion Criteria:~* History or evidence of clinically significant disorder, condition or disease that would pose a risk or interfere with the study~* Pregnant or lactating~* Clinically significant heart, hepatic or renal disease~* History of cancer within 5 years of screening~* Infection that is not controlled despite antibiotics or other treatment~* History of bleeding diathesis within the last 6 months of Day 1~* Known history of human immunodeficiency virus, hepatitis B or C~* Concern's for subjects compliance~* Other conditions that might put the subject at high risk for treatment complications or reduce the chance to obtain data required~* Placed on a lung transplant list~* Previous participation in an idiopathic pulmonary fibrosis clinical trial other than for simtuzumab~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simtuzumab (Type: EXPERIMENTAL): Participants will receive simtuzumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, ≥18- years of age at the time of Avelumab treatment initiation~2. Patients with locally advanced or metastatic urothelial cancer with any histology (histologically confirmed, unresectable locally advanced or metastatic urothelial carcinoma and/or documented Stage IV disease (per American Joint Committee on Cancer/International Union for Cancer Control TNM system1 19-21) at the start of first-line chemotherapy)~3. Patients who have completed first-line platinum-based chemotherapy with no evidence of disease progression according to medical chart (ie, with a SD, PRor complete response \[CR\]).~4. Patients who are receiving or have received at least one dose of Avelumab as the firstl ine maintenance therapy according to label indication~5. Patients with ongoing treatment with Avelumab who provided written informed consent allowing the data collection. For decease patients and those who are lost to follow-up, an approved ICF waiver is allowed.~Exclusion Criteria:~* Patients who have participated in any interventional clinical trial of a drug or device within 28- days prior to the start of Avelumab maintenance therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Advanced or Metastatic Urothelial Cancer (Type: None): Patients with Advanced or Metastatic Urothelial Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tricyclic Antidepressants (TCAs) on Gastric Emptying

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sixty normal subjects, males and females within the ages of 18 to 65 years, will be studied. Normal control subjects will be recruited for voluntary participation through poster advertisements. A normal subject is defined as a person with no gastrointestinal (GI) symptoms; no prior history of peptic ulcer disease or irritable bowel disease; no previous history of a GI motility disorder (including, but not limited to, achalasia, gastroparesis); on no medications for GI disorders; no history of prior surgery on the GI tract (esophagus, stomach, large or small intestine); and a normal physical examination.~Exclusion Criteria:~* History of a motility disorder (including, but not limited to, achalasia, gastroparesis)~* History of peptic ulcer disease~* Symptoms referable to gastric dysmotility (nausea, vomiting, early satiety, heartburn, postprandial abdominal distension)~* Use of medications that may affect GI motor function (beta adrenergic receptor blockers, calcium channel blockers, histamine type 2 receptor antagonists, proton pump inhibitors, prokinetic agents, antidepressants, and the use of narcotic analgesics)~* Regular use of nonsteroidal anti-inflammatory medications~* Use of monoamine oxidase inhibitors~* Pregnancy or breast feeding~* Prior gastrointestinal surgery (except appendectomy)~* Contraindications to amitriptyline or desipramine, which will be exclusion criteria to the study, include hypersensitivity or allergy to any tricyclic drug, concomitant therapy with a monoamine oxidase inhibitor, recent myocardial infarction, myelography within previous 48 hours, or lactation. In addition, history of prostate problems, history of urinary retention, known glaucoma, history of seizures, or thyroid or liver dysfunction are exclusionary criteria to the use of TCAs and to entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: t

Study Arms:
- Nortriptyline (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient, her person-of-trust, must have given his/her consent and signed the consent form / inclusion decision made by the investigator when a person-of-trust is absent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is able to fluently read and speak French~* Blood loss \> 500ml and sulprostone treatment is insufficient at 20 minutes~* Duration of pregnancy \> 32 weeks of amenorrhea~* Uterine atony~Exclusion Criteria:~* The patient is participating in another study except for the followin studies: ElastoMAP, ElastoDéclench, Papillo PMA, GrossPath, LXRs, DGPostPartum~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient cannot read French~* The patient was transferred to another center not among the centers participating in this study~* The patient has a contraindication for a treatment used in this study (Sulprostone), or an incompatible treatment combination~* The patient has a contraindication for third level techniques~* The patient has at least one of the following conditions: chorioamnionitis, cervical cancer, uterine rupture, anatomical abnormality preventing the introduction of the device, purulent infection of the vagina, cervix or uterus.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- With Bakri balloon (Type: EXPERIMENTAL): Patients randomized to this arm will be treated using the Bakri balloon.~Intervention: Bakri balloon
- Without Bakri balloon (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will receive routine care not including the Bakri Balloon.~Intervention: Routine Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 50 years in age~* Leg/buttock/groin pain, with or without back pain, that can be completely relieved by flexion such as when sitting in a chair.~* Zurich Claudication Questionnaire Score ≥ 2.0,~* Neurogenic intermittent claudication secondary to moderate lumbar spinal stenosis~* Has completed at least 6 months conservative therapy~Exclusion Criteria:~* Axial back pain only without leg/buttock/groin pain~* Has had any prior lumbar spine surgery at any level~* Significant scoliosis, defined as Cobb angle \> 10°~* Spondylolisthesis \> Grade 1 or isthmic spondylolisthesis at affected level~* Osteoporosis~* Morbid obesity, defined as BMI \> 40 kg/m2

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): In-Space
- 2 (Type: ACTIVE_COMPARATOR): X STOP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Length of Cervical Collar Treatment for Traumatic Sub-axial Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a newly diagnosed (within 5 days of injury) fracture in vertebra C3-C7 with SLIC score 1-3~* Patients must be abel to give their consent to participate in the study~Exclusion Criteria:~* Unstable cervical fractures in need of surgery~* SLIC score \>3~* Fractures of the spinous process and the transverse process in the cervical spine~* Stable fractures in in the C3-C7 vertebra combined with fractures of the C0-C2 vertebra~* Pathological fractures in the cervical spine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 6 weeks (Type: OTHER): This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
- 12 weeks (Type: OTHER): This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Female or male subjects, at least 27 years old.~2. Confirmed diagnosis of intra-anal HSIL at least 3 months prior to screening and confirmed by histopathology (with p16 positive staining)~3. Intra-anal HSIL are visible and evaluable by HRA at the time of screening, and no lesion(s) is suspicious for invasive cancer.~4. For HIV-positive subjects, CD4 count must be at least 200/mm3 with undetectable (\<50 copies/mL) viral load within the 3 months prior to enrollment. Subjects must be on a stable regimen of antiretroviral drugs for the 3 months prior to enrollment.~Exclusion Criteria:~1. Women who are pregnant, plan to become pregnant in the next 3 months, or lactating females.~2. Received topical treatment or ablative procedures for aHSIL in the 6 months prior to enrolment.~3. History of cancer involving the anogenital region, or history of other cancers that have not been fully resolved and free of symptoms in the past 5 years~4. History of genital herpes with \> 3 outbreaks per year.~5. Plan to have excision or ablation of the lesion(s) within 3 months of enrolment.

- Gender: ALL
- Minimum Age: 27 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1 - Multiple Ascending Dose(MAD) (Type: EXPERIMENTAL): Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
- Dose 2 - Multiple Ascending Dose(MAD) (Type: EXPERIMENTAL): Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
- Dose 3 - Multiple Ascending Dose(MAD) (Type: EXPERIMENTAL): Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study in Participants With Acute Migraines Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants between the ages of 18 and 65 years, inclusive.~* Participants who have migraine headaches, with or without aura (diagnosis according the International Classification of Headache Disorders-II), for at least 1 year.~* Participants who have had 2-8 migraine attacks on average per month for the last 3 months (but less than 15 headache days per month).~* Participants who are willing and able to comply with the study schedule and requirements.~* Participants who speak, read, and understand English sufficiently well and are willing to provide written informed consent.~* Participants who in the opinion of the principal investigator are in good general health.~* Venous access should be sufficient to allow blood sampling as per protocol.~Exclusion Criteria:~* Participants who do not or may not tolerate 5HT1 agonist treatments, with known hypersensitivity to sumatriptan (as discussed with the investigator).~* Female participants who have a positive pregnancy test at screening or pre- dose evaluation, or are breastfeeding.~* History or presence of significant medical illnesses as determined by the investigator.~* Participants with a current clinical diagnosis of major psychiatric disease.~* Regular use of known drugs of abuse; use of opiates for migraine rescue (no more than two times per month) is permissible.~* Blood donation of 500 milliliter (mL) or greater of whole blood products within 4 weeks of study commencement, during the study, or 4 weeks following the study.~* Investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.~* Consumption of more than three units of alcohol per day where one unit is defined as a 12 ounces (oz) beer, 4 oz wine, or 2 oz of alcohol spirit liquor.~* Are unwilling or unable to comply with the use of a diary to directly record data from the participant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Fall Detection Device in Isolated Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Person over 75 living at home alone in ESSONNE (France) and having fallen at least one time during the 3 months preceding the inclusion in the study.~* Person having signed a free and enlightened consent~Exclusion Criteria:~* Person living in institution (nursing home, retirement home...)~* Person under 75~* Person with severe cognitive impairment (MMS \< 15)~* Person under protection as incapable (guardianship or trusteeship)~* Person not affiliated to a social insurance

- Gender: ALL
- Minimum Age: 76 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Persons equipped (Type: EXPERIMENTAL): Precocious fall detection device
- Persons non-equipped (Type: NO_INTERVENTION): No fall detection device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Current or former smoker who has smoked ≥ 30 pack-years (i.e., 1 pack per day for ≥ 30 years)~  * A former smoker is defined as one who has stopped smoking for ≥ 1 year~* C-reactive protein level \> 1.2 mg/L~* One or more areas of dysplasia with a surface diameter \> 1.2 mm on autofluorescence bronchoscopy~* No carcinoma in situ or invasive cancer on bronchoscopy~* No abnormal spiral chest CT scan suspicious of lung cancer~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Willing to take Polyphenon E or placebo twice a day regularly~* Willing to undergo bronchoscopy and spiral chest CT scan~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine normal~* Bilirubin normal~* AST and ALT normal~* Alkaline phosphatase normal~* No chronic active hepatitis or liver cirrhosis~* No severe heart disease (e.g., unstable angina or chronic congestive heart failure)~* No ongoing gastric ulcer~* No acute bronchitis or pneumonia within the past month~* No known reaction to xylocaine, salbutamol, midazolam, or alfentanil~* No known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients~* No medical condition, such as acute or chronic respiratory failure or bleeding disorder, that, in the opinion of the investigator, could jeopardize patient safety during study participation~PRIOR CONCURRENT THERAPY:~* No concurrent consumption of \> 7 cups of tea a week~* No other concurrent natural health products containing green tea compounds~* No concurrent antiarrhythmic agents~* No concurrent anticoagulants, such as warfarin or heparin

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological diagnosis of colon or rectal cancer from either the colon or rectum or a metastatic site (beyond the colon or rectum)~* Evidence of adequate organ function (such as liver, kidneys, etc.)~Exclusion Criteria:~* Diagnosis of anal cancer~* Patients who are candidates for surgery~* Patients who have received previous treatments~* Pregnant or lactating women~* History of chronic disease(s) or other serious medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transient Elastography and Variceal Bleeding

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent form signed~* Social security affiliation~* Variceal bleeding with hematemesis or melena within 24 hours of inclusion~* Age \> 18 years~* Scheduled to undergo endoscopy within 24 hours of hospital admission~Exclusion Criteria:~* Hepatocarcinoma~* Upper Gastro Intestinal bleeding for other causes than variceal bleeding~* Concomitant disease with a life expectancy of less than 45 days~* Rebleeding within 24 hours after first endoscopy~* Technical failure of transient elastography

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fibroscan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues